Welcome to our dedicated page for Ibio SEC filings (Ticker: IBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The iBio, Inc. (NASDAQ: IBIO) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Forms 10‑K, 10‑Q and 8‑K, as they appear on the EDGAR system. iBio is a preclinical-stage biotechnology company that uses AI and advanced computational biology to develop precision antibody therapies for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases, and its filings offer detailed insight into this strategy.
Through annual and quarterly reports, investors can review iBio’s description of its AI Drug Discovery Platform, preclinical pipeline programs such as IBIO‑610 and IBIO‑600, risk factors, liquidity and capital resources. Current reports on Form 8‑K capture material events, including financing transactions, Nasdaq listing compliance updates, new preclinical data disclosures, changes to corporate presentations and the results of annual stockholder meetings. The company’s definitive proxy statements (DEF 14A) provide information on board structure, executive compensation and governance matters.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as preclinical data updates, capital-raising terms, and changes in risk disclosures. Real-time updates ensure that new IBIO filings, including Form 4 insider transaction reports when available, appear promptly in the feed.
By using this IBIO filings page, investors and researchers can efficiently navigate iBio’s regulatory history, from its business description and pipeline details to financing structures and governance decisions, while AI-generated overviews make complex SEC documents more accessible.
iBio, Inc. filed a prospectus supplement for an offering that includes Series G warrants and Series H warrants (the latter issuable upon exercise of Series G warrants) and related pre-funded warrants or common stock. The underwriting fees include a 6.0% commission on aggregate gross proceeds. The document discloses outstanding equity-linked instruments as of March 31, 2025 and August 11, 2025, including stock options, restricted stock units, previously issued pre-funded warrants and warrants, and shares reserved under the 2023 Omnibus Equity Incentive Plan, which create dilution potential. The prospectus describes intended use of proceeds, risk factors (including that warrants may expire worthless), tax withholding rules for non-U.S. holders, and lists incorporated SEC filings and periodic reports. The supplement also highlights the company’s AI-based epitope engine, its capital-efficient strategy emphasizing strategic partnerships, tech licensing and advancing in-house preclinical programs.
ADAR1-affiliated investors report beneficial ownership of 1,794,055 shares of iBio, Inc., representing 9.9% of the outstanding common stock. The holding comprises 54,819 shares held directly by ADAR1 Partners, LP and 1,739,236 shares issuable upon conversion of milestone warrants held by ADAR1 Partners, LP. The filing states that 716,904 additional shares underlying milestone warrants are excluded because their exchange or exercise is subject to a 9.99% beneficial ownership limitation.
The reporting entities are ADAR1 Capital Management, LLC (investment adviser), ADAR1 Capital Management GP, LLC (general partner) and Daniel Schneeberger (manager), each disclosing shared voting and dispositive power over the 1,794,055 shares. The ownership percentage is calculated on a stated base of 16,219,281 shares outstanding.
iBio, Inc. (Nasdaq: IBIO) has filed a Form 424(b)(3) prospectus dated June 23, 2025 to register the resale of up to 11,253,370 shares of common stock. The shares correspond to the same number of shares underlying New Warrants issued in a private placement completed on April 30, 2025 under an Inducement Agreement signed April 29, 2025.
- Warrant terms: exercise price $0.86, immediately exercisable, five-year term.
- Potential company proceeds: up to approximately $9.7 million in cash should all warrants be exercised.
- Use of prospectus: enables the Selling Stockholders (and their transferees) to sell shares at market, related, or negotiated prices; iBio will not receive sale proceeds but will cover registration expenses.
- Selling mechanics: shares may be sold via underwriters, brokers, or directly in public or private transactions as detailed in the “Plan of Distribution.”
- Listing information: IBIO last traded at $0.771 on June 20, 2025, below the warrant exercise price.
The filing satisfies iBio’s contractual obligation to register the shares, preserves potential capital inflow from future warrant exercises, and signals possible dilution if the warrants are exercised. Investors should consult the “Risk Factors” section on page 5 and the company’s SEC filings for further details.
On June 24, 2025, iBio, Inc. (Nasdaq: IBIO) filed a Form 8-K to inform the market that it has released an updated corporate presentation, dated June 2025. The slide deck, furnished as Exhibit 99.1, will be used in discussions with investors, analysts and other stakeholders. The filing is made under Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). iBio states that the presentation includes forward-looking statements covered by the Private Securities Litigation Reform Act of 1995 and that the company assumes no obligation to update the material. No financial results, strategic transactions or other material developments are disclosed in this report.
The SEC has declared iBio's Form S-3 registration statement effective as of June 23, 2025, at 5:00 P.M. The registration statement was filed under file number 333-288000.
Form S-3 is a simplified security registration form used by companies that have already met certain reporting requirements. This effectiveness notice indicates that:
- iBio can now proceed with its planned securities offering
- The company has satisfied SEC registration requirements
- The registration statement has been reviewed and approved by the SEC
This filing suggests iBio is preparing to raise capital through the public markets, though specific details about the type and amount of securities to be offered would be found in the original S-3 filing and related prospectus.